Menopause is confirmed when FSH levels exceed 30 mIU/mL and estradiol drops below 30 pg/mL in women who have missed periods for 12 consecutive months. Anti-Mullerian hormone (AMH) levels below 0.1 ng/mL also indicate ovarian reserve depletion consistent with menopause. Clinical studies show that 95% of postmenopausal women have FSH levels above 25 mIU/mL, while premenopausal women typically maintain FSH below 10 mIU/mL. The North American Menopause Society reports that estradiol levels in postmenopausal women average 15-20 pg/mL, compared to 30-400 pg/mL during reproductive years. LH levels also rise significantly during menopause, typically exceeding 20 mIU/mL. These hormone changes occur gradually over perimenopause, which can last 4-8 years before reaching complete menopause around age 51 in most women.
Key Takeaways
- FSH above 30 mIU/mL and estradiol below 30 pg/mL confirm menopause status
- AMH levels below 0.1 ng/mL indicate depleted ovarian reserve
- Hormone testing requires 12 months of missed periods for accurate interpretation
- Multiple tests over time provide more reliable results than single measurements
- Hormone therapy options in 2026 include both traditional and innovative approaches
FSH and LH Levels During Menopause
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rise dramatically as ovarian function declines. FSH levels above 30 mIU/mL consistently indicate menopause, with many women reaching 40-50 mIU/mL or higher. Research from the Study of Women's Health Across the Nation (SWAN) involving 3,302 women showed that FSH levels begin rising 2-3 years before final menstrual periods. LH levels typically exceed 20 mIU/mL in postmenopausal women, though FSH remains the more reliable marker. The pituitary gland produces these elevated hormone levels in response to declining ovarian estrogen production. Some women exploring hormone optimization also consider peptide therapy options alongside traditional hormone replacement approaches.Estradiol and Progesterone Changes
Estradiol levels drop significantly during menopause, falling from reproductive levels of 30-400 pg/mL to postmenopausal levels of 15-30 pg/mL or lower. This represents roughly a 90% decline in estrogen production. Progesterone levels become virtually undetectable, typically measuring less than 1 ng/mL compared to 5-20 ng/mL during the luteal phase of premenopausal cycles. The Massachusetts Women's Health Study tracked 2,570 women and found that estradiol levels below 30 pg/mL correlated strongly with menopausal symptoms and bone density changes. Testosterone levels also decline, dropping approximately 50% from premenopausal levels, which can affect energy and muscle mass.Anti-Mullerian Hormone (AMH) Testing
AMH provides the most accurate assessment of ovarian reserve and menopause status. Levels below 0.1 ng/mL indicate severely diminished ovarian function consistent with menopause. Women in their 20s typically have AMH levels of 2-4 ng/mL, which decline predictably with age. A study of 17,120 women published in Human Reproduction found that AMH levels below 0.7 ng/mL predicted menopause within 5 years with 85% accuracy. Unlike FSH and estradiol, AMH remains stable throughout the menstrual cycle, making it ideal for single-point testing. Many clinicians prefer AMH testing combined with symptom assessment for menopause diagnosis. Women considering hormone optimization may also explore complementary approaches like Sermorelin therapy for growth hormone support.Timing and Interpretation of Hormone Tests
Accurate hormone testing requires specific timing considerations. FSH and estradiol should be measured on cycle day 3-5 for premenopausal women, while postmenopausal women can test any time. The American College of Obstetricians and Gynecologists recommends waiting 12 months after final menstrual period before confirming menopause through hormone testing. Multiple measurements over 2-3 months provide more reliable results than single tests due to hormone fluctuations during perimenopause. Women using hormonal contraceptives need to discontinue these medications for 6-8 weeks before accurate testing. Laboratory reference ranges may vary, but most facilities use similar cutoff values for menopausal diagnosis. Some women also explore innovative approaches like Ipamorelin therapy as part of comprehensive wellness strategies.Frequently Asked Questions
What FSH level confirms menopause?
FSH levels above 30 mIU/mL combined with 12 months of missed periods confirm menopause. Most laboratories use 25-30 mIU/mL as the threshold, though levels often reach 40-50 mIU/mL in postmenopausal women. Single elevated FSH readings during perimenopause may fluctuate, so multiple tests over several months provide more accurate diagnosis.
Personalized hormone therapy for women
Work with a licensed provider to find the right hormone optimization plan for your symptoms and goals.
Start Free Assessment →View data table
| Category | Symptom Improvement (%) | Detail |
|---|---|---|
| Week 2 | 30 | Mood stabilization begins |
| Month 1 | 50 | Hot flash reduction |
| Month 3 | 72 | Significant symptom relief |
| Month 6 | 88 | Full therapeutic benefit |
Can you have normal estrogen levels during menopause?
Postmenopausal women maintain low estrogen levels, typically 15-30 pg/mL, not normal reproductive levels of 30-400 pg/mL. Estradiol levels above 30 pg/mL in women over 50 may indicate continued ovarian function or exogenous hormone use. Consistently low estrogen confirms ovarian senescence characteristic of menopause.
How accurate is AMH testing for menopause?
AMH testing shows 85% accuracy in predicting menopause within 5 years when levels drop below 0.7 ng/mL. Levels below 0.1 ng/mL indicate current menopause with high reliability. AMH provides more consistent results than FSH because it doesn't fluctuate with menstrual cycles, making it particularly useful during perimenopause transitions.
Do testosterone levels change during menopause?
Testosterone levels decline approximately 50% during menopause, dropping from premenopausal levels of 15-70 ng/dL to 8-35 ng/dL postmenopausally. This reduction contributes to decreased libido, energy, and muscle mass. Some women benefit from testosterone replacement therapy as part of comprehensive hormone management strategies during menopause.
When should hormone testing be done for menopause?
Hormone testing should occur after 12 months of missed periods for definitive menopause diagnosis. Earlier testing during irregular periods can help assess perimenopause status. FSH and estradiol should be drawn on cycle days 3-5 if periods remain, while AMH can be tested any time regardless of cycle status.
Sources
- Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168. PMID: 22344196
- Randolph JF Jr, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition. J Clin Endocrinol Metab. 2011;96(3):746-754. PMID: 21159842
- Freeman EW, et al. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012;97(5):1673-1680. PMID: 22378815
- Santoro N, et al. Body size and ethnicity are associated with menstrual cycle length. J Clin Endocrinol Metab. 2004;89(6):2622-2631. PMID: 15181033
- North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767-794. PMID: 35797481
- Burger HG, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8):2832-2838. PMID: 10946891
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. PMID: 24463691
- Tepper PG, et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition. J Clin Endocrinol Metab. 2012;97(8):2872-2880. PMID: 22659249